Research!American launches 2016 election blog

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RESEARCH!AMERICA launched its Campaign for Cures 2016 election blog and an online interactive map featuring hundreds of quotes on medical progress from candidates across the political spectrum running for national office.

Managed by former USA Today senior editor and health reporter Janice Lloyd, the blog features election news, survey data, commentary and analysis of presidential and congressional races in key states on topics relevant to medical progress.

Campaign for Cures partners include Pfizer, the Society for Neuroscience, Alzheimer’s Association, PhRMA, American Heart Association, American Cancer Society Cancer Action Network, University of Maryland School of Medicine, The University of Chicago Pritzker School of Medicine, American Public Health Association, American Association for Cancer Research, Cold Spring Harbor Laboratory, EveryLife Foundation for Rare Diseases, The American College of Neuropsychopharmacology, Penn Medicine, The Whitehead Institute and The American Association of Colleges of Pharmacy.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login